Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totaling 26,983 shares, a drop of 39.9% from the September 30th total of 44,911 shares. Based on an average trading volume of 255,560 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.
Analysts Set New Price Targets
SAUHY has been the subject of a number of recent analyst reports. Citigroup reissued a “sell” rating on shares of Straumann in a research report on Wednesday, October 21st. BMO Capital Markets began coverage on shares of Straumann in a research note on Wednesday, July 8th. They issued an “outperform” rating for the company. Berenberg Bank raised shares of Straumann to a “strong-buy” rating in a report on Thursday, September 17th. Deutsche Bank Aktiengesellschaft cut shares of Straumann from a “buy” rating to a “hold” rating in a report on Friday, August 21st. Finally, The Goldman Sachs Group upgraded shares of Straumann from a “neutral” rating to a “buy” rating in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on SAUHY
Straumann Stock Performance
Shares of OTCMKTS SAUHY traded up $0.47 during mid-day trading on Monday, reaching $12.26. The company’s stock had a trading volume of 35,987 shares, compared to its average volume of 149,185. Straumann has a 52 week low of $9.44 and a 52 week high of $13.61. The stock has a fifty day moving average of $11.42 and a two-hundred day moving average of $11.66.
Straumann Company Profile
Straumann Group is a Switzerland-based dental technology company headquartered in Basel. Founded in 1954, the company develops, manufactures and distributes products used in tooth replacement, restorative dentistry and oral tissue regeneration. Its offerings are designed for dental professionals, laboratories and patients across a range of clinical applications.
The company’s portfolio includes dental implants, implant-supported prosthetics, biomaterials for bone and tissue regeneration, orthodontic aligners and digital dentistry solutions.
See Also
- Five stocks we like better than Straumann
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
